Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5892838 | 0.85 | SLC6A1 (0.34) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL27701676 | 0.85 | SLC6A1 (0.34) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27824226 | 0.84 | SLC6A1 (0.33) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL538525 | 0.83 | DPP4 (0.31) | KDM4EMAPTKMT2AATMNOS2 | |
| SCHEMBL4383814 | 0.81 | SLC6A1 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL15542301 | 0.81 | SLC6A1 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL3272707 | 0.81 | SLC6A1 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL7348922 | 0.78 | ATM (0.43) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL11235384 | 0.77 | SLC6A1 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28737023 | 0.76 | PARP1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | disclosed |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-11-13 | — | — | US | disclosed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNH2, KCNA6, KCNA3 | SLC6A1 444/4885SLC6A11 786/4885TSHR 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.